Twitter | Search | |
Search Refresh
Coherus BioSciences Jul 12
"To overcome ongoing misinformation efforts directed against and to help support acceptance... strong education must be provided to patients, providers, and the broader health care industry." Read more via :
Reply Retweet Like
PRI Jul 14
Great to see our own 's work cited in this breakdown of our new study: Struggle to Gain Share in the U.S., Analysis Shows via
Reply Retweet Like
Christine Simmon Jul 8
Despite approvals, patients continue to lose on access, in large part due to brand actions designed to limit uptake and protect profits. We must continue to highlight these practices and encourage congressional action:
Reply Retweet Like
Seamus Dunne 55m
Waiting for Godot; a biosimilar perspective
Reply Retweet Like
Stephanie Caird Jul 16
Very interesting talk by Dr Schneider of ⁦⁩ on the regulation of
Reply Retweet Like
Uppsala Monitoring 1h
With the patents on many well-known biological drugs about to expire, the race is on among drug developers to create generic versions, or . But making a copy of a complex biological drug is no trivial matter. Learn more in this video.
Reply Retweet Like
Larry Abrams Jul 14
Per , mostly have been a "market failure" as measured by market share. However, entrants like have been a GREAT SUCCESS FOR PATIENTS (despite 6% share) because they drive 15% YoY / 2 yr price drops by incumbents like Remicade
Reply Retweet Like
U.S. Pharmacopeia 7h
More than 50 biosimilars have been approved in the EU, where public quality standards play a role in enhancing patient/provider confidence in these medicines. Download this PDF on why public quality standards are critical to .
Reply Retweet Like
Mark Emalfarb 3h
Reply Retweet Like
Pavol 12h
Many challenges stand in the way of bringing new to market. Get info on the current state of the global biosimilars industry.
Reply Retweet Like
Boehringer Ingelheim 6h
Biologics and are produced using a sophisticated, highly technical, multistep process
Reply Retweet Like
mph501 Jul 16
Decrease the time to complete clinical development while increasing the probability of success through an early, risk-mitigated approach. Learn more about the Analytical Master Files and see a list of target innovators in the Education Center
Reply Retweet Like
LudovicoMD 3h
Permanente physician leader Sameer Awsare, MD, does a great job explaining in this video. This is one way we can address high .
Reply Retweet Like
Technavio 4h
Due to the increasing approvals for and , the global will register a CAGR of 7%. Read@ to know how the market will grow by $ 58.95 million during 2019-2023
Reply Retweet Like
mAbxience Jul 15
are a safe, effective and efficient medical treatment, represent an opportunity to treat more patients with appropriate therapies and help to maintain the financial sustainability of healthcare systems worldwide.
Reply Retweet Like
Laura Joszt 7h
What's the latest on ? A joint podcast between and takes a look at the first half of 2019, including the loss of from FDA and how many biosimilars have actually made it to the US market
Reply Retweet Like
Biosimilars Forum Jul 11
NEW from @PacficResearch: details how can save the U.S up to $71B over a decade. Learn how:
Reply Retweet Like
CenterForBiosimilars Jul 12
Catch up on this week's top news in .
Reply Retweet Like
Timothy Caulfield 13h
Interesting review regarding the clinical and ethical challenges of switching from to cc
Reply Retweet Like
Biosimilars Forum 24h
DYK: By reducing out-of-pocket costs, could save taxpayers $5.2B over the next decade. Let's
Reply Retweet Like